Contact

Our portfolio

Skyline Dx

Skyline Dx is a molecular diagnostics company focusing on oncology and infectious diseases. Their platform-agnostic tests range from PCR to Next Generation Sequencing technologies. Skyline Dx partners with discovery and commercial companies to develop and distribute their diagnostic tests. The company is dedicated to advancing precision medicine through innovative molecular diagnostics.

  • Institute: Amsterdam UMC
Industry: Diagnostics, Oncology
  • Founding year: 2013
Visit website

Want to get in contact about Skyline Dx?

We’re happy to connect. Reach out to our investment manager working with the team to learn more or explore potential opportunities.

Browse all investment managers

Marc Roelofs

Life Science & Health

Our portfolio

Check out similar ventures

AMI Pharma
Advancing new therapeutics for Type 1 Diabetes and autoimmune diseases.
Phlox Therapeutics
Developing RNA-based therapies for rare genetic heart diseases.
longform.ai
Using AI to restructure audio data, such as podcasts and webinars.
AviSia Therapeutics
Modulating immune responses with glycan-modified antigens for the treatment of Type 1 Diabetes.
AMI Pharma
Advancing new therapeutics for Type 1 Diabetes and autoimmune diseases.
Phlox Therapeutics
Developing RNA-based therapies for rare genetic heart diseases.
longform.ai
Using AI to restructure audio data, such as podcasts and webinars.
AviSia Therapeutics
Modulating immune responses with glycan-modified antigens for the treatment of Type 1 Diabetes.
Explore full AAV portfolio
Contact